COL18A1 and non-small cell lung carcinoma: Among them, aCECs have been put forward as a promising biomarker for prognosis of NSCLC.1, 28, 29, 30 Our previous studies have also demonstrated that aCECs (CD105) is a powerful predictive marker in chemotherapy with rh‐endostatin in NSCLC, so aCECs was chosen in this study again.